Literature DB >> 9642130

Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells.

K Iijima1, M Yoshizumi, J Ako, M Eto, S Kim, M Hashimoto, N Sugimoto, Y Q Liang, N Sudoh, K Toba, Y Ouchi.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma), a member of nuclear receptors, is expressed at a high level in adipose tissue and plays an important role in adipocyte differentiation. In the present study, we identified the expression of PPARgamma in rat aortic smooth muscle cells (RASMC) using reverse transcription-polymerase chain reaction and gel mobility shift assay. In addition, to investigate whether PPARgamma in RASMC is functional or not, we examined the effect of two specific ligands for PPARgamma, a thiazolidinedione anti-diabetic agent, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2, on the transcriptional activity of PPAR responsive element (PPRE). A significant increase in the activity of PPRE by addition of these ligands was found. These results suggest that in RASMC, target genes for PPARgamma may be activated by specific ligands for PPARgamma through PPRE in their promoters. In conclusion, PPARgamma is expressed and functional in vascular smooth muscle cells. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642130     DOI: 10.1006/bbrc.1998.8794

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

Review 2.  PPAR-gamma agonists and diabetic nephropathy.

Authors:  Yahua Zhang; Youfei Guan
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

Review 3.  Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.

Authors:  J Plutzky
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

4.  Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

Authors:  Andreas M Beyer; Gary L Baumbach; Carmen M Halabi; Mary L Modrick; Cynthia M Lynch; Thomas D Gerhold; Shams M Ghoneim; Willem J de Lange; Henry L Keen; Yau-Sheng Tsai; Nobuyo Maeda; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2008-02-19       Impact factor: 10.190

Review 5.  Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Authors:  Jean-Pierre Després; Isabelle Lemieux; Sander J Robins
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Role of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR.

Authors:  Zivar Yousefipour; Adebayo Oyekan; Mohammad Newaz
Journal:  Am J Nephrol       Date:  2009-05-05       Impact factor: 3.754

7.  The possible role of peroxisome proliferator-activated receptor gamma in heart failure.

Authors:  Natsuhiko Ehara; Koh Ono; Tatsuya Morimoto; Teruhisa Kawamura; Mitsuru Abe; Koji Hasegawa
Journal:  Exp Clin Cardiol       Date:  2004

8.  The study of ginsenoside on PPARgamma expression of mononuclear macrophage in type 2 diabetes.

Authors:  Hai-xiang Ni; Ning-juan Yu; Xue-hui Yang
Journal:  Mol Biol Rep       Date:  2009-10-10       Impact factor: 2.316

Review 9.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

10.  Peroxisome proliferator-activated receptors in diabetic nephropathy.

Authors:  Shinji Kume; Takashi Uzu; Keiji Isshiki; Daisuke Koya
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.